A new rapid test for hepatitis C could help identify many more patients who could be cured of the deadly disease, but its use may be limited unless insurers' reimbursement rises to cover its high cost ...
A recent blood-based hepatitis C virus assay on Nuclein's DASH system highlighted its on-device sample prep, among other features that have been driving its adoption.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback